Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions.

Monoclonal antibodies have revolutionized cancer therapy and are integral part of standard therapies. Despite their clinical efficacy, not all cancer patients benefit from established antibody therapies. Preclinical and clinical findings revealed that Fc-mediated effector functions play an essential role in antibody therapy. Therefore, current antibody-based immunotherapies can be optimized by antibody Fc engineering to generate next-generation monoclonal antibodies with tailor-made effector functions. The enhancement of Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) may increase efficiency of prospective antibody-based immunotherapies.